πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 416 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9574012

AGR2 blocking antibody and use thereof

Sanofi (China) Investment Co., Ltd. Shanghai Branch Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9567393

Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9527903

Engineered antibody constant domain molecules

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512212

Bispecific antibody fragments for neurological disease proteins and methods of use

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9505826

Modified antibody with improved half-life

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9499608

Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS pene

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9453078

Modified antibody compositions, methods of making and using thereof

CytomX Therapeutics, Inc. Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9441048

Antibody for 3β€²-isoLM1 and 3β€²,6β€²-iso-LD1 gangliosides

The United States of America, as represented by the Secretary, Health and Human Services Β· Granted Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9399672

Hepatitis C virus neutralizing antibody

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9359429

Anti-cyanobacteria recombinant antibody polypeptide, gene thereof, and preparation method

PROTEIN DESIGN LAB, LTD. Β· Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9358306

Photosensitizing antibody-fluorophore conjugates

The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353176

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9308256

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9290572

Integrin Ξ±-VΞ²8 neutralizing antibody

The Regents of the University of California Β· Granted Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273143

Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EG

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9266928

Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved ant

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9259488

Anti-C3d antibody conjugates and methods of detecting complement activation

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9249217

Bispecific EGFRvIII x CD3 antibody engaging molecules

The United States of America, as represented by the Secretary, DHHS Β· Granted Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9242014

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment c

The Regents of the University of California Β· Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9181338

Human antibody specific for IL-1alpha

XBIOTECH INC. Β· Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9157916

Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using E

The Board of Regents of the University of Texas System Β· Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9139634

Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activiti

The Regents of the University of California Β· Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9101670

Conjugates of an anti-TNF-Ξ± antibody

Nektar Therapeutics Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9095608

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD

The Regents of the University of Colorado Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted